Agilio: Diagnosis and Treatment Guidance February 2026 Update

This update contains 6 significant changes and 12 minor changes.

Significant Changes:

• Contraception – IUS/IUD — reviewed. A literature search was conducted in September 2025 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic. More detail has been added to the sections on follow-up advice, new-onset pelvic pain and uterine perforation in line with guidance from the College of Reproductive and Sexual Health. No major changes to recommendations have been made.
• Gilbert’s syndrome — reviewed. A literature search was conducted in October 2025 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. No major changes to the recommendations have been made.
• Itch – widespread — reviewed. A literature search was conducted in November 2025 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. The recommendations have been updated in line with current evidence in the literature.
• Obstructive sleep apnoea syndrome — minor update. Table 1 in the treatment section has been updated for clarity. The recommendations remain the same.
• Platelets – abnormal counts and cancer — reviewed. A literature search was conducted in October 2025 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last version of this topic. The topic structure has been amended to aid navigation and reduce duplication. The management sections have been expanded and updated in line with current evidence in the literature.
• Support for adult carers — reviewed. A literature search was conducted in October 2025 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. No major changes to recommendations have been made, but the topic has been restructured for clarity.

Minor Changes: 

• Bipolar disorder — minor update. Revised wording regarding monitoring of hba1c and prolactin for some atypical antipsychotics.
• Boils, carbuncles, and staphylococcal carriage — minor update. Minor typographical error corrected.
• Cervical screening — minor update. Section ‘What is the Cervical Screening Programme’ also updated to a 5 year recall.
• Child maltreatment — minor update. Definition for whether a child is “independently mobile” has been added, in line with the December 2025 update to Child maltreatment: when to suspect maltreatment in under 18s.
• Chronic obstructive pulmonary disease— minor update. Table 1 in the treatment section has been updated for clarity. The recommendations remain the same.
• Hypertension — minor update. Minor change to the order of referral criteria in the management section.
• Influenza – seasonal— minor update. Information on when antivirals can be prescribed has been clarified.
• Prostate cancer — minor update. Added detail on the range of potential false negative testing for PSA.
• Psychosis — minor update. Revised wording regarding monitoring of hba1c and prolatin for some atypical antipsychotics.
• Shingles — minor update. Information on eligible cohorts for shingles vaccination has been updated in line with updated NHS guidance.
• Smoking cessation — minor update. Added detail to advise that although e-cigarettes cannot currently be prescribed or supplied by NHS smoking cessation clinics the majority of local authority smoking cessation clinics do provide them as part of a harm reduction approach.
• Urticaria — minor update. Added more information on titrating dose of antihistamines in the prescribing section.